Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: Immunohistochemical analysis of a new molecular marker

Breast Cancer Research and Treatment

Volumn 98, Issue 2, 2006, Pages 231-240

  Wells, Wendy A ^a   Schwartz, Gary N ^a   Morganelli, Peter M ^a,b   Cole, Bernard F ^a   Gibson, Jennifer J ^a   Kinlaw, William B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chromosome 11q13; Gene amplification; Lipogenesis; Tumor markers

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; HORMONE; MOLECULAR MARKER; NUCLEAR PROTEIN; STEROID RECEPTOR; THYROID HORMONE RESPONSIVE SPOT 14 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CYCLIN D1; DIETARY FATS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33745923520     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9154-z     Document Type: Article

References (35)

1. Cunningham B, Moncur J, Huntington J, Kinlaw WB: "Spot 14" protein: a metabolic integrator in normal and neoplastic cells. Thyroid 8: 815-825, 1998
2. Kinlaw W, Church J, Harmon J, Mariash C: Direct evidence for a role of the "spot 14" protein in the regulation of lipid synthesis. J Biol Chem 270: 16615-16618, 1995
3. Brown SB, Maloney M, Kinlaw WB: "Spot 14" protein functions at the pretranslational level in the regulation of hepatic metabolism by thyroid hormone and glucose. J Biol Chem 272: 2163-2166, 1997
4. Zhu Q, Anderson G, Mucha G, Parks E, Metkowski J, Mariash C: The spot 14 protein is required for de novo lipid synthesis in the lactating mammary gland. Endocrinol 146: 3343-3350, 2005
5. Moncur J, Park J, Mohandes TK, Memoli V, Kinlaw W: The "spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers. Proc Natl Acad Sci USA 95: 6989-6994, 1998
6. Kuhajda F, Piantadosi S, Pasternack G: Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. NEJM 321: 636-641, 1989
7. Kuhajda F: Fatty-acid synthase and human cancer: New perspectives on its role in tumor biology. Nutrition 16: 202-208, 2000
8. Pizer E, Wood F, Heine H, Romanstev F, Pasternak G, Kuhajda F: Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56: 1189-1193, 1996
9. Pizer E, Jackisch C, Wood F, Pasternak G, Davidson N, Kuhajda F: Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56: 2745-2747, 1996
10. Kridel S, Axelrod F, Rozenkrantz N, Smith J: Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075, 2004
11. Hinds P, Dowdy S, Eaton E, Arnold A, Weinberg R: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 91: 709-713, 1994
12. Petty W, Dragnev K, Memoli V, et al Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers. Clin Cane Res 10: 7547-7554, 2004
13. Martel P, Bingham C, McGraw C, Baler C, Morganelli P, Meng M, Armstrong J, Moncur J, Kinlaw W: S14 protein in breast cancer cells: direct evidence of regulation by SREBP-1c, super-induction with progestin, and implication on cell growth. Exp Cell Res 312: 278-288, 2006
14. Kinlaw WB, Ling NC, Oppenheimer JH: Identification of rat S14 protein and comparison of its regulation with that of mRNA S14 employing synthetic peptide antisera. J Biol Chem 264: 19779-19783, 1989
15. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Soerensen F: The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 176: 343-352, 1995
16. Milgraum L, Witters L, Pasternack G, Kuhajda F: Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Canc Res 3: 2115-2120, 1997
17. Menard S, Pupa S, Campiglio M, Tagliabue E: Biologic and therapeutic role of Her2 in cancer. Oncogene 22: 6570-6578, 2003
18. Schuuring E, Verhoeven E, van Tintern H, et al Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 52: 5229-5234, 1992
19. Champeme M, Bieche I, Lizard S, Lidereau R: 11q13 amplification in local recurrence of human primary breast cancer. Genes, Chromosome Cancer 12: 128-133, 1995
20. Alo P, Visca P, Marci A, Mangoni A, Botti C, Di Tondo U: Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer 77: 474-482, 1995
21. Sanchez-Rodriguez J, Kanininda-Tshilumbu J, Santos A, Perez-Castillo A: The spot 14 protein inhibits growth and induces differentiation and cell death of human MCF-7 breast cancer cells. Biochem J 390(Pt 1): 57-65, 2005
22. Heemers H, Vanderhoydonc F, Heyns W, Verhoeven G, Swinnen J: Progestins and androgens increase expression of spot 14 in T47-D breast tumor cells. Biochem Biophys Res Commun 269: 209-212, 2000
23. Kumar-Sinha C, Ignatoski K, Lippman M, Ethier S, Chinnaiyan A: Transcriptome analysis of Her2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63: 132-139, 2003
24. Moncur J, Park J, Maloney M, Mohandas TK, Kinlaw WB: Assignment of the human "spot 14' gene to 11q13.5 by fluorescence in situ hybridization. Cytogen Cell Genet 78: 131-132, 1997
25. Dickson C, Fantl V, Gillett C, et al Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90: 43-50, 1995
26. Gillet C, Fantl V, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54: 1812-1817, 1994
27. Al-Kuraya K, Schrami P, Torhorst J, Tapia C, Sauter G: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540, 2004
28. Courjal F, Cuny M, Simony-Lafontaine J, et al Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57: 4360-4365, 1997
29. Michalides R, Hageman P, van Tintern H, et al A clincopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. British J Cancer 73: 728-734, 1996
30. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G: Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69: 92-99, 1996
31. Seshadri R, Lee C, Hui R, McCaul K, Horsfall D, Sutherland R: Cyclin D1 amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2: 1177-1844, 1996
32. Chlebowski R, Blackburn G, Elashoff R, et al Dietary fat reduction in postmenopausal women with primary breast cancer: Phase III Women's Interventioon Nutrition Study (WINS). Proc Am Soc Clin Oncol 23: 3s, 2005
33. Weiss L, Hoffman G, Schreiber R, et al Fatty-Acid Biosynthesis in Man, a Pathway of Minor Importance. J Biol Chem 367: 905-912, 1986
34. Perou C, Jeffrey S, van de Rijn M, et al Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96: 9212-9217, 1999
35. Desai K, Xiao N, Wang W, et al Initiating oncogenic event determines gene expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99: 6967-6972, 2002